[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Komuro T, Okamoto S: Pure intracerebral mass lesion of adult T-cell leukemia/lymphoma--case report. Neurol Med Chir (Tokyo); 2010;50(6):492-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She underwent radiation therapy and chemotherapy after local recurrence and metastasis to an optic nerve.
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20587977.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Pérez-Alvarez MJ, Arriola-Villalobos P, Reche-Frutos J, García-Sánchez J: [Choroidal metastasis from a breast carcinoma. Diagnosis and follow-up with optical coherence tomography and fluorescein angiography and autofluorescence with HRA-II (Heidelberg Retina Angiograph)]. Arch Soc Esp Oftalmol; 2009 May;84(5):267-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis from a breast carcinoma. Diagnosis and follow-up with optical coherence tomography and fluorescein angiography and autofluorescence with HRA-II (Heidelberg Retina Angiograph)].
  • CLINICAL CASE: A 69-year-old woman developed choroidal metastasis from a breast carcinoma 2 years after the initial diagnosis, surgery and chemotherapy.
  • After treatment with palliative chemotherapy and external radiotherapy, we used fluorescein angiography (FA) and optical coherence tomography (OCT) to evaluate the resolution of the serous retinal detachment, as well as a later relapse in the optic nerve.
  • DISCUSSION: OCT is useful in the follow-up of choroidal metastasis after treatment.
  • However, OCT imaging is limited by the initial choroidal location of metastasis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Choroid Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / analogs & derivatives. Doxorubicin / administration & dosage. Female. Fluorescein Angiography. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Mastectomy, Radical. Optic Nerve Neoplasms / secondary. Palliative Care. Retinal Detachment / etiology. Tomography, Optical Coherence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466689.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; H64JRU6GJ0 / trofosfamide; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down


3. Krishnakumar S, Mallikarjuna K, Desai N, Muthialu A, Venkatesan N, Sundaram A, Khetan V, Shanmugam MP: Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol; 2004 Dec;88(12):1521-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIM: Retinoblastoma is the commonest primary intraocular tumour in children.
  • Chemotherapy now plays a big part in the treatment of these tumours.
  • METHODS: Among 60 retinoblastomas, 40 tumours were not subjected to preoperative or postoperative chemotherapy and 20 tumours were subjected to postoperative chemotherapy.
  • In this cohort 27 tumours had no invasion and 33 tumours had invasion of choroid, optic nerve, and orbit.
  • Both P-gp and LRP were negative in three tumours with invasion, which had later developed bone marrow metastasis.
  • There was no correlation between P-gp and LRP expression with invasion, differentiation and laterality of the tumours and response to treatment.
  • CONCLUSION: Retinoblastoma expresses P-gp and LRP intrinsically before chemotherapy and none of these proteins predicted the response to chemotherapy.
  • [MeSH-major] Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy
  • [MeSH-minor] Bone Marrow Neoplasms / secondary. Child. Child, Preschool. Drug Resistance, Multiple. Female. Humans. Immunohistochemistry / methods. Infant. Male. Neoplasm Invasiveness. Treatment Outcome. Vault Ribonucleoprotein Particles

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jan;18(1):12-7 [10623688.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1499-508 [9816326.001]
  • [Cites] Surv Ophthalmol. 2002 Jan-Feb;47(1):1-16 [11801265.001]
  • [Cites] Zhonghua Yan Ke Za Zhi. 2001 Jul;37(4):256-8 [11864431.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):879-86 [12644825.001]
  • [Cites] Ophthalmology. 2003 Jun;110(6):1237-40 [12799253.001]
  • [Cites] Curr Eye Res. 2003 Dec;27(6):345-53 [14704918.001]
  • [Cites] Cancer Surv. 1986;5(1):25-46 [2885085.001]
  • [Cites] Anticancer Res. 1989 Mar-Apr;9(2):469-74 [2751270.001]
  • [Cites] Ophthalmology. 1991 Sep;98(9):1425-31 [1682862.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1475-9 [7680954.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Apr;9(2):xi-xii [7642462.001]
  • [Cites] N Engl J Med. 1995 Nov 23;333(21):1417-9 [7477126.001]
  • [Cites] Nat Med. 1995 Jun;1(6):578-82 [7585126.001]
  • [Cites] Arch Ophthalmol. 1996 Nov;114(11):1321-8 [8906022.001]
  • [Cites] Arch Ophthalmol. 1996 Nov;114(11):1330-8 [8906023.001]
  • [Cites] Arch Ophthalmol. 1996 Nov;114(11):1348-56 [8906025.001]
  • [Cites] Ophthalmology. 1996 Dec;103(12):1989-97 [9003332.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2325-30 [9192801.001]
  • [CommentIn] Br J Ophthalmol. 2005 Jun;89(6):784 [15923533.001]
  • (PMID = 15548804.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  • [Other-IDs] NLM/ PMC1772413
  •  go-up   go-down


Advertisement
4. Shields CL, Meadows AT, Leahey AM, Shields JA: Continuing challenges in the management of retinoblastoma with chemotherapy. Retina; 2004 Dec;24(6):849-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuing challenges in the management of retinoblastoma with chemotherapy.
  • There is a trend away from enucleation and external beam radiotherapy toward focal conservative treatments involving primary chemoreduction in conjunction with thermotherapy and cryotherapy.
  • This is related to earlier detection of the disease, recognition of more effective chemotherapeutic agents, more focused local treatment modalities, and, most importantly, knowledge of the long-term risks of external beam radiotherapy.
  • Enucleation is still preferable for retinoblastoma that fills most of the eye, especially when the disease is unilateral or when there is concern for tumor invasion into the optic nerve, choroid, or orbit.
  • The most important recent advance in the management of retinoblastoma is the use of intravenous chemotherapy for tumor reduction, a technique of neoadjuvant chemotherapy termed "chemoreduction."
  • This is followed by tumor consolidation with focal measures such as thermotherapy, cryotherapy, and plaque radiotherapy.
  • This strategy provides reduced tumor volume and often permits consolidation with methods other than radiotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Retinal Neoplasms / drug therapy. Retinoblastoma / drug therapy
  • [MeSH-minor] Brachytherapy. Child. Child, Preschool. Combined Modality Therapy. Humans. Hyperthermia, Induced. Infant. Laser Coagulation. Neoplasm Metastasis / prevention & control

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15579981.001).
  • [ISSN] 0275-004X
  • [Journal-full-title] Retina (Philadelphia, Pa.)
  • [ISO-abbreviation] Retina (Philadelphia, Pa.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 110
  •  go-up   go-down


5. Balwierz W, Pietrys D, Romanowska-Dixon B, Kobylarz J, Pawińska-Wasikowska K, Moryl-Bujakowska A: [Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma]. Przegl Lek; 2010;67(6):404-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of combined chemotherapy and local ophtalmic therapy for intraocular retinoblastoma].
  • Until recently chemotherapy was used as adjuvant therapy after enucleation in cases with extraretinal spread of the disease (uveal extension, orbital extension, neoplastic infiltrates of the optic nerve at resection line, intracranial metastasis, generalized disease).
  • Recent experience has proved that use of chemotherapy for intraocular retinoblastoma before local treatment (so called "chemoreduction") has allowed not only to decrease number of enucleations and indications for external beam irradiation or limit the extension of local therapy, but also increase chances for vision preservation and decrease the risk of severe complications.
  • Enucleation before chemotherapy was necessary in 9 (8.5%) cases, and in 22 more children the eye had to be removed after 1-2 courses of chemotherapy.
  • In 68 remaining children (with 70 involved eyes) VEC (vincristine, etoposide, carboplatin) chemotherapy combined with delayed local therapy (cryotherapy, photocoagulation, brachytherapy) was employed.
  • First-line chemotherapy combined with the local treatment should be standard treatment for intraocular retinoblastoma groups I - IV.
  • More effective therapy is required for R-E eye group V cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Eye Neoplasms / drug therapy. Retinoblastoma / drug therapy
  • [MeSH-minor] Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Cryotherapy. Etoposide / administration & dosage. Eye Enucleation. Female. Humans. Infant. Infant, Newborn. Light Coagulation. Male. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344770.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


6. Kramer CK, Ferreira N, Silveiro SP, Gross JL, Dora JM, Azevedo MJ: Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma. Arq Bras Endocrinol Metabol; 2010;54(5):498-501
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma.
  • Metastatic tumors involving the pituitary gland are an uncommon finding and occur in up to 1% of all pituitary tumor resections.
  • Five years ago, he underwent a right radical nephrectomy for renal cell carcinoma, followed by chemotherapy and radiotherapy for lung and parotid metastases.
  • On ophthalmologic examination, there was a left abducens nerve palsy and bitemporal hemianopia.
  • Magnetic resonance imaging demonstrated a sellar mass with suprasellar cistern extension compressing the optic chiasm.
  • The patient underwent a transsphenoidal tumor resection that revealed renal cell carcinoma.
  • This case illustrates that metastatic pituitary lesions can mimic typical symptoms and signs of pituitary macroadenoma.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Pituitary Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694412.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


7. Papageorgiou KI, Sinha A, Ioannidis AS, Davidson NG: Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report. Cases J; 2009;2:9143
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastases from HER2 positive breast carcinoma and the response to combination therapy with Paclitaxel and Trastuzumab: a case report.
  • PURPOSE: Breast cancer is the most common tumour to metastasize to the uveal tract.
  • The mean survival period after diagnosis of metastasis to the eye, ranges from 10 to 32 months.
  • However, recent advances in therapy including the use of monoclonal antibody therapy, will hopefully improve treatment outcomes and prolong survival rates.
  • METHODS: We report a case of a 45 year old woman with a HER2 positive breast cancer, who developed two metastatic lesions in the left choroid, and the left optic nerve sheath.
  • She underwent treatment with a combination of chemotherapy (Paclitaxel) and anti-HER2 monoclonal antibodies (Trastuzumab).
  • RESULTS: Nine months after treatment, a B-scan showed resolution of the superior choroidal focus, as well as absence of blood flow within the optic nerve sheath.
  • CONCLUSION: The patient underwent a combined treatment of chemotherapy and Trastuzumab to increase the response rate.
  • Nine months following the therapy her vision was stable, whilst one focus of the tumour in the affected eye, had regressed.
  • The favourable response highlights the significant impact of this new therapy, as an alternative to external beam radiotherapy in patients with ocular metastasis from HER2 (+) breast cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):264-71 [12888048.001]
  • [Cites] Adv Exp Med Biol. 2003;532:253-68 [12908564.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):623-7 [2065283.001]
  • (PMID = 20062660.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803940
  •  go-up   go-down


8. Soysal HG, Markoç F: Invasive squamous cell carcinoma of the eyelids and periorbital region. Br J Ophthalmol; 2007 Mar;91(3):325-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To review the clinical and histopathological features, treatment and outcomes of squamous cell carcinoma of the eyelids.
  • Age, sex, risk factors, duration of symptoms, size and location of lesion, previous recurrences, presence of perineural invasion (PNI) and orbital invasion, histological subtype, inflammatory response of peritumoral tissue were recorded and analysed.
  • 63 patients underwent surgery, whereas others were treated with external radiotherapy or chemotherapy.
  • Recurrence or presence of residual tumour rate was 22.4%, most of them had orbital invasion.
  • Regional lymph node metastasis was detected in 5 (6.6%) cases.
  • CONCLUSIONS: Advanced deep local invasion was not rare in this study, as a result of treatment delay and previous inadequate treatments.
  • Adverse prognostic factors associated with secondary orbital invasion are previous recurrences, longer duration of lesion, larger lesion size, and presence of PNI.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Optic Nerve / pathology. Orbit / pathology. Paranasal Sinuses / pathology. Prognosis. Retrospective Studies. Sclera / pathology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1992 Jun;26(6):976-90 [1607418.001]
  • [Cites] Australas Radiol. 2000 Aug;44(3):296-302 [10974723.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):479-84 [9082276.001]
  • [Cites] Ophthalmology. 1997 Sep;104(9):1457-62 [9307641.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):746-50 [10201597.001]
  • [Cites] Cancer. 1999 May 15;85(10):2114-8 [10326687.001]
  • [Cites] Arch Ophthalmol. 1963 Jun;69:693-7 [13927762.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7322-7 [16243803.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):465-72 [16428488.001]
  • [Cites] Arch Ophthalmol. 1997 Jan;115(1):75-8 [9006429.001]
  • [Cites] Am J Ophthalmol. 1992 Feb 15;113(2):123-33 [1550179.001]
  • [Cites] J Neuroophthalmol. 2000 Dec;20(4):240-1 [11130747.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2088-98; quiz 2099-100, 2121 [11713084.001]
  • [Cites] Br J Ophthalmol. 2002 Oct;86(10):1161-5 [12234899.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1736-42 [14583778.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):493-501 [14968119.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):617-23 [15051191.001]
  • [Cites] Ophthalmology. 2004 Oct;111(10):1930-2 [15465559.001]
  • [Cites] Ophthalmic Surg. 1980 Oct;11(10):671-81 [7005795.001]
  • [Cites] Surv Ophthalmol. 1986 May-Jun;30(6):349-65 [3523806.001]
  • [Cites] Med J Aust. 1986 Mar 3;144(5):235-9 [3587093.001]
  • [CommentIn] Br J Ophthalmol. 2007 Mar;91(3):276-7 [17322464.001]
  • (PMID = 17020898.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1857650
  •  go-up   go-down


9. Kaur H, Buettner H, Salomao DR, Marks RS: Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma. Am J Ophthalmol; 2007 Feb;143(2):369-70
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
  • PURPOSE: To report transcleral orbital invasion by a radiation- and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
  • METHODS: A 51-year-old female was found to have choroidal metastasis from a previously unknown primary pulmonary adenocarcinoma.
  • She underwent external beam radiation treatment with a total dose of 40 Gray (Gy), delivered in 20 fractions over 28 days, followed by adjuvant chemotherapy with gemcitabine and carboplatin.
  • After completing two of the three scheduled chemotherapy cycles, the choroidal lesion was observed to have increased in size.
  • RESULTS: A transvitreal aspiration biopsy of the choroidal lesion confirmed the diagnosis of metastatic pulmonary adenocarcinoma.
  • Histopathology revealed invasion through scleral emissary channels to the retrobulbar tissue and through the optic nerve substance itself.
  • CONCLUSIONS: Despite appropriate external beam radiation therapy (EBRT) and chemotherapy, pulmonary adenocarcinoma metastases to the choroid can continue to grow and may invade the orbit transclerally.
  • [MeSH-major] Adenocarcinoma / secondary. Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Orbital Neoplasms / pathology. Sclera / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance. Eye Enucleation. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiation Tolerance. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258542.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Haritoglou C, Mueller AJ: [Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report]. Ophthalmologe; 2003 Apr;100(4):326-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of an uveal metastatic tumor from breast cancer during chemotherapy--a case report].
  • [Transliterated title] Visusanstieg nach Chemotherapie einer Aderhautmetastase eines Mammakarzinoms.
  • BACKGROUND: Choroidal metastases generally respond well to radiation treatment.
  • However, a deterioration of visual acuity after radiation must be taken into account in lesions involving the optic nerve.
  • In these cases, alternatives to radiation, which is a palliative treatment in most cases anyway, should be considered.
  • MATERIAL AND METHODS: We present the clinical and echographic findings of a case of a 39-year-old patient with choroidal metastasis from breast carcinoma.
  • RESULTS: We observed a regression of the metastasis and an improvement of visual acuity from 0.2 to 1.0 under systemic chemotherapy.
  • Echography showed a decrease of tumor height and increasing reflectivity indicating progressive scarring of the lesion.
  • CONCLUSIONS: Especially in cases in which a deterioration of visual acuity after radiation must be expected, the follow-up during systemic chemotherapy alone might be considered an alternative option, as it not only might preserve vision, but also allows an "in vivo" monitoring of the success of the chemotherapy applied.
  • [MeSH-major] Breast Neoplasms. Choroid Neoplasms / secondary. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Combined Modality Therapy. Diphosphonates / administration & dosage. Diphosphonates / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Fluorescein Angiography. Follow-Up Studies. Humans. Tamoxifen / administration & dosage. Tamoxifen / therapeutic use. Time Factors. Visual Acuity

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12682767.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Diphosphonates; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; OYY3447OMC / pamidronate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Balwierz W, Kobylarz J, Starzycka M, Dluzniewska A: [Results of combined chemotherapy and local ophtalmic therapy of children with intraocular retinoblastoma]. Med Wieku Rozwoj; 2001 Jul-Sep;5(3 Suppl 1):15-23
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of combined chemotherapy and local ophtalmic therapy of children with intraocular retinoblastoma].
  • Until recently chemotherapy in retinoblastoma was used as adjuvant therapy after enucleation in cases with extraretinal spread of the disease (weal extension, orbital extension, neoplastic infiltrates of the optic nerve at resection line, intracranial metastasis and generalized disease).
  • Recent experience has proved that use of chemotherapy for intraocular retinoblastoma before local treatment (so called "chemoreduction") has allowed not only to decrease the number of enucleations and indications for external beam irradiation or limit the extension of local therapy; but also to increase the chances for vision preservation and to decrease the risk of severe complications.
  • Enucleation before chemotherapy was necessary in 9 cases, and in two more children the eye had to be removed after 1-2 courses of chemotherapy.
  • In 11 remaining children (with 18 involved eyes) VEC chemotherapy combined with delayed local therapy (cryotherapy, photocoagulation, brachytherapy) was employed.
  • First-line chemotherapy combined with local treatment should be standard treatment for intraocular retinoblastoma groups I and II.
  • More effective therapy is required for advanced cases particularly for Reese-Ellsworth eye group V.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Retinal Neoplasms / therapy. Retinoblastoma / therapy
  • [MeSH-minor] Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Cryotherapy. Etoposide / administration & dosage. Eye Enucleation. Humans. Infant. Infant, Newborn. Light Coagulation. Remission Induction. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12004148.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Wabbels B, Demmler A, Seitz J, Woenckhaus M, Bloss HG, Lorenz B: Unilateral adult malignant optic nerve glioma. Graefes Arch Clin Exp Ophthalmol; 2004 Sep;242(9):741-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for optic nerve glioma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral adult malignant optic nerve glioma.
  • INTRODUCTION: Adult malignant optic nerve gliomas are rare and rapidly fatal visual pathway tumours.
  • They represent a clinical entity different from the more common childhood benign optic nerve gliomas, which are frequently associated with neurofibromatosis I.
  • MRI showed intraorbital and intracranial swelling of the right optic nerve.
  • Resection of the intracranial part of the right optic nerve up to the chiasm revealed anaplastic astrocytoma grade III.
  • Within 1 year, the patient died of leptomeningeal metastasis despite radiotherapy.
  • Clinical and MRI evaluation of the left eye and optic nerve were normal at all times.
  • DISCUSSION: Unilateral adult malignant glioma of the optic nerve is exceptional.
  • The final diagnosis was only confirmed by optic nerve biopsy.
  • In the literature, only one patient has been reported with a unilateral tumour manifestation; he was lost to follow-up 3 months later.
  • To date, 44 case reports of adult malignant optic nerve glioma have been published, either malignant astrocytoma or glioblastoma.
  • These tumours can mimic optic neuritis in their initial presentation.
  • On MRI images, malignant glioma cannot be distinguished from optic nerve enlargement due to other causes.
  • Although radiotherapy appears to prolong life expectancy, all presently available treatment options (radiation, surgery, radio-chemotherapy) are of limited value.
  • [MeSH-major] Optic Nerve Glioma / pathology. Optic Nerve Neoplasms / pathology

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1949 Nov;33(11):701-8, illust [15406720.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):731-5 [718470.001]
  • [Cites] Neurosurg Rev. 1995;18(4):273-5 [8927245.001]
  • [Cites] J Clin Neuroophthalmol. 1985 Dec;5(4):238-43 [3001150.001]
  • [Cites] Br J Ophthalmol. 1967 Oct;51(10):703-6 [6054905.001]
  • [Cites] Am J Ophthalmol. 1980 Feb;89(2):284-92 [6243868.001]
  • [Cites] Br J Ophthalmol. 1973 Oct;57(10):788-91 [4361475.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1 Suppl):110 [12546402.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):923-5 [7472567.001]
  • [Cites] J Neuroophthalmol. 2001 Mar;21(1):1-7 [11315972.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1987;224:59-60 [3509024.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] Surg Neurol. 1984 Jan;21(1):83-7 [6689816.001]
  • [Cites] Neurosurgery. 1982 Dec;11(6):787-9 [6298650.001]
  • [Cites] Minn Med. 1982 Mar;65(3):155-9 [7087953.001]
  • [Cites] J Neurosurg. 1989 Feb;70(2):277-9 [2643688.001]
  • [Cites] Neurology. 1988 Jul;38(7):1071-4 [3386825.001]
  • [Cites] Arch Ophthalmol. 1976 Jul;94(7):1142-4 [180944.001]
  • [Cites] Brain. 1973;96(1):121-32 [4695718.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):1046-8 [9672989.001]
  • [Cites] Acta Neurol Scand. 1999 Nov;100(5):350-3 [10536925.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1673-6 [7502973.001]
  • [Cites] Arch Ophthalmol. 1988 Dec;106(12 ):1701-5 [3196211.001]
  • [Cites] Br J Ophthalmol. 1973 Apr;57(4):253-64 [4707622.001]
  • [Cites] J Neurosurg. 1996 May;84(5):898-9 [8622175.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):498-503 [1330262.001]
  • (PMID = 15085353.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 29
  •  go-up   go-down


13. Armenian SH, Panigrahy A, Murphree AL, Jubran RF: Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. Pediatr Blood Cancer; 2008 Oct;51(4):479-84
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis.
  • BACKGROUND: In North America, retinoblastoma rarely presents with gross clinical evidence of tumor involving the optic nerve.
  • Extent of microscopic tumor infiltration into the postlaminar optic nerve is a significant risk factor for metastasis, especially if there is tumor at the cut end.
  • Due to poor outcomes in patients with metastatic disease, historical treatment for patients with clinical evidence of extraocular optic nerve involvement has included upfront enucleation followed by aggressive adjuvant chemotherapy.
  • Additional orbital irradiation is advocated for individuals with optic nerve involvement at the surgical margin.
  • Little is known about the role of neoadjuvant therapy in the setting of orbital optic nerve enhancement on magnetic resonance imaging (MRI) at diagnosis.
  • METHODS: A retrospective review of consecutive retinoblastoma cases at Childrens Hospital Los Angeles over a 3-year period (2004-2006) found to have gadolinium contrast enhancement in the proximal portion of optic nerve on MRI at diagnosis.
  • Two had secondary glaucoma of a sufficient degree to cause an enlarged eye (buphthalmos).
  • All patients received neoadjuvant chemotherapy prior to enucleation.
  • CONCLUSIONS: Neoadjuvant chemotherapy is well tolerated prior to enucleation of retinoblastoma-containing eyes associated with contrast enhancement of the proximal optic nerve on MRI at diagnosis.
  • Such an approach may be used to decrease intensity or duration of chemotherapy and need for external beam radiation.
  • [MeSH-major] Optic Nerve Neoplasms / diagnosis. Optic Nerve Neoplasms / drug therapy. Retinal Neoplasms / diagnosis. Retinal Neoplasms / drug therapy. Retinoblastoma / diagnosis. Retinoblastoma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18478574.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Konuk O, Pehlivanli Z, Yirmibesoglu E, Erkal HS, Erekul S, Unal M: Compressive optic neuropathy due to orbital metastasis of a sacral chordoma: case report. Ophthal Plast Reconstr Surg; 2005 May;21(3):245-7
MedlinePlus Health Information. consumer health - Optic Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compressive optic neuropathy due to orbital metastasis of a sacral chordoma: case report.
  • He had a history of recurrent sacral chordoma for 1 year that had previously been treated with combined surgical excision, chemotherapy, and radiation therapy.
  • MRI showed compression of the optic nerve by an orbital mass that proved to be an orbital metastasis of his sacral chordoma.
  • The tumor mass was excised subtotally, and adjuvant orbital radiation therapy was administered.
  • [MeSH-major] Chordoma / secondary. Nerve Compression Syndromes / etiology. Optic Nerve Diseases / etiology. Orbital Neoplasms / secondary. Sacrococcygeal Region / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Exophthalmos / etiology. Exophthalmos / therapy. Humans. Male. Neoplasm Recurrence, Local. Ophthalmologic Surgical Procedures. Vision Disorders / etiology. Vision Disorders / therapy

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942507.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Banneux N, Bonnet S: [Optic disc metastasis from pulmonary adenocarcinoma]. Bull Soc Belge Ophtalmol; 2007;(305):79-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Optic disc metastasis from pulmonary adenocarcinoma].
  • However, the optic nerve remains an exceptional site of metastases.
  • Metastases to the optic disc account only for 4.5% of all intraocular metastases and are most of the time accompanied by an adjacent juxtapapillary choroidal component.
  • The left optic disc shows a diffuse yellow thickening and flame-shaped hemorrhages.
  • The diagnosis of an optic disc metastasis was retained according to the ophthalmoscopy and various complementary investigations.
  • DISCUSSION: The optic disc metastasis can occur in a well-known cancer history but may sometimes be the first manifestation of it.
  • The mean age at the time of ocular diagnosis is 55 years.
  • The prognosis is poor because optic nerve metastases occur in advanced metastatic cancer.
  • The mean treatments are external radiotherapy associated with systemic chemotherapy.
  • CONCLUSION: Presence of an optic disc lesion may suggest the possibility of a papillary metastasis despite the lack of a cancer history.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Lung Neoplasms / pathology. Optic Nerve Neoplasms / diagnosis. Optic Nerve Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018431.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


16. Lindegaard J, Heegaard S, Toft PB, Nysom K, Prause JU: Malignant transformation of a medulloepithelioma of the optic nerve. Orbit; 2010 Jun;29(3):161-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a medulloepithelioma of the optic nerve.
  • OBJECTIVE: To describe a case of malignant transformation of a medulloepithelioma of the optic nerve.
  • A benign non-teratoid medulloepithelioma of the optic nerve was surgically removed.
  • Light microscopy and immunohistochemistry now revealed a malignant medulloepithelioma.
  • The boy was further treated with chemotherapy and radiotherapy and is still alive 36 months after primary surgery.
  • RESULTS: Medulloepithelioma of the optic nerve is extremely rare.
  • Unlike intraocular medulloepithelioma, all have been malignant tumours.
  • This is the first case described of a benign medulloepithelioma of the optic nerve, later transforming into a malignant tumour.
  • One third of patients with medulloepithelioma of the optic nerve have died from direct intracranial spread or metastasis to the central nervous system (CNS).
  • CONCLUSIONS: Medulloepithelioma of the optic nerve should be considered malignant despite morphology with tendency to spread to the CNS.
  • Furthermore; it should be considered as a differential diagnosis when observing a tumour of the optic nerve in a child.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / pathology. Neuroectodermal Tumors, Primitive / pathology. Optic Nerve Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Child, Preschool. Exophthalmos / diagnosis. Exophthalmos / etiology. Eye Enucleation / methods. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Orbit Evisceration / methods. Radiotherapy, Adjuvant. Risk Assessment. Stem Cell Transplantation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497085.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Makimoto A: Results of treatment of retinoblastoma that has infiltrated the optic nerve, is recurrent, or has metastasized outside the eyeball. Int J Clin Oncol; 2004 Feb;9(1):7-12
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of retinoblastoma that has infiltrated the optic nerve, is recurrent, or has metastasized outside the eyeball.
  • Since the development of chemotherapy regimens for patients with retinoblastoma started in the 1950s, various agents and regimens have been employed for various kinds of patients.
  • Chemotherapy has been employed for:.
  • (1) patients with high-risk features for metastases, such as patients with optic nerve involvement, (2) patients with orbital involvement, and (3) patients with distant metastasis.
  • With the addition of appropriate chemotherapies to the conventional treatment modalities such as enucleation and radiotherapy, patients with advanced retinoblastoma are expected to obtain a survival benefit.
  • Moreover, a new modality combined with autologous stem cell support allowed us to use high-dose alkylating agents such as thiotepa, melphalan, and cyclophosphamide, which resulted in better prognosis for patients with metastatic retinoblastoma.
  • Because of the small number of patients with retinoblastoma and the diversity of the disease characteristics in individual patients, there have been no clinical trials to determine whether to recommend a particular regimen, or to identify specific criteria in patients who would benefit from chemotherapy.
  • Well-designed prospective controlled trials are warranted to establish a standard treatment strategy for patients with extraocular retinoblastoma.
  • [MeSH-major] Neoplasm Recurrence, Local / secondary. Neoplasm Recurrence, Local / therapy. Optic Nerve / pathology. Retinal Neoplasms / pathology. Retinal Neoplasms / therapy. Retinoblastoma / pathology. Retinoblastoma / therapy
  • [MeSH-minor] Drug Therapy / trends. Eye / pathology. Humans. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Stem Cell Transplantation / trends. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15162820.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 30
  •  go-up   go-down


18. Lim K, Ilsen PF: Optic disk edema in a patient with non-Hodgkin's lymphoma: is there a metastasis to the brain? Optometry; 2001 Jan;72(1):25-35
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic disk edema in a patient with non-Hodgkin's lymphoma: is there a metastasis to the brain?
  • This case report will present the manifestations and treatment of non-Hodgkin's lymphoma and review the differential diagnoses of bilateral disk edema.
  • Dilated funduscopy revealed early left optic disk edema; edema of the right optic nerve head was questionable.
  • The patient had pulmonary nodules noted on a recent chest x-ray that were thought to be cancerous; this raised the suspicion of a metastasis to the brain or orbit.
  • The patient did not return until about 10 weeks later, at which time he presented with a history significant for newly-diagnosed intermediate-grade non-Hodgkin's lymphoma.
  • He had begun chemotherapy one month before the second examination at our clinic; methotrexate therapy for CNS metastasis had been provided at the time of the spinal taps.
  • At the second visit, there was marked progression of the swelling of the left optic disk and mild swelling of the right disk.
  • The patient's disk swelling resolved completely by the end of his six months of chemotherapy.
  • CONCLUSION: This is a unique presentation of a patient at high risk for brain metastasis, in which laboratory and radiologic studies failed to provide adequate supportive evidence for the conclusions drawn from clinic observations.
  • Bilateral disk edema in a patient with a history of non-Hodgkin's lymphoma is strongly suggestive of a metastatic tumor to the brain causing increased intracranial pressure.
  • [MeSH-major] Brain Neoplasms / secondary. Lymphoma, Non-Hodgkin / complications. Papilledema / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11217003.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sahin A, Kiratli H: Choroidal metastasis as a first sign of recurrence in a patient with gastric adenocarcinoma. Can J Ophthalmol; 2007 Apr;42(2):331-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroidal metastasis as a first sign of recurrence in a patient with gastric adenocarcinoma.
  • A solitary choroidal tumour was found, but no clinically detectable metastasis initially.
  • COMMENTS: This patient represents a rare occurrence of metastatic gastric adenocarcinoma to the choroid and optic nerve, developing as a first sign of systemic recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392868.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Malik M, Prabhakar R, Sharma DN, Rath GK: Retinoblastoma with cerebrospinal fluid metastasis treated with orbital and craniospinal irradiation using IMRT. Technol Cancer Res Treat; 2006 Oct;5(5):497-501
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma with cerebrospinal fluid metastasis treated with orbital and craniospinal irradiation using IMRT.
  • Clinical examination and computed tomography revealed a unilateral retinoblastoma involving the left globe.
  • He underwent enucleation of the left eye and was referred for adjuvant radiotherapy in view of optic nerve infiltration up to the line of resection.
  • However, he did not report for treatment and presented six months later with a recurrent mass in the left orbit with intracranial extension.
  • Cerebrospinal fluid (CSF) cytology was positive for malignant retinoblastoma cells.
  • He received multiagent chemotherapy with vincristine, carboplatin, and etoposide along with intrathecal methotrexate.
  • Although the recurrent orbital mass reduced significantly with chemotherapy, malignant cells persisted in the CSF.
  • He was subsequently treated using intensity modulated radiation therapy (IMRT) to treat the left orbital mass along with craniospinal axis irradiation.
  • Computed tomography done at three and nine months after completion of radiotherapy showed complete disappearance of orbital tumor.
  • CSF cytology also showed no evidence of malignant cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16981792.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hormozi AK, Ghazisaidi MR, Hosseini SN: Unusual presentation of peripheral primitive neuroectodermal tumor of the maxilla. J Craniofac Surg; 2010 Nov;21(6):1761-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of peripheral primitive neuroectodermal tumor of the maxilla.
  • The peripheral primitive neuroectodermal tumor (pPNET) is a rare and highly malignant soft tissue neoplasm in children and young adults.
  • A 28-year-old woman was presented with the pPNET of the maxilla and metastasis.
  • Two years after diagnosis, she experienced diplopia, and then magnetic resonance imaging was done, which showed a mass in the optic chiasma and parasellar region.
  • The typical appearance resembled large noncalcified soft tissue masses in the magnetic resonance image and computed tomographic scan of the maxilla.
  • She was treated with surgery, chemotherapy, radiation therapy, and gamma knife.
  • She was under close observation since then (approximately 8 mo), and there has been no recurrence of tumor up to now.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Optic Chiasm / pathology. Optic Nerve Neoplasms / secondary. Radiosurgery. Radiotherapy, Adjuvant. Sella Turcica / pathology. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119416.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J, Shields JA: Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol; 2002 Jul;120(7):923-31
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postenucleation adjuvant therapy in high-risk retinoblastoma.
  • PURPOSE: The main purpose of this study was to determine the efficacy of postenucleation adjuvant therapy in preventing metastasis in cases of high-risk retinoblastoma.
  • Of 1020 consecutive patients with retinoblastoma had were managed at a referral center between January 1974 and December 1999, 80 (8%) of those analyzed had unilateral sporadic cases that were treated by primary enucleation and that had high-risk characteristics for metastasis on histopathology reports (anterior chamber seeding, iris infiltration, ciliary body infiltration, massive choroidal infiltration, invasion of optic nerve lamina cribrosa, retrolaminar optic nerve invasion, invasion of optic nerve transection, scleral infiltration, and extrascleral extension).
  • The main outcome measure was the development of metastasis at a minimum follow-up period of 12 months.
  • Forty-six patients (58%) had received postenucleation adjuvant therapy (chemotherapy with or without orbital external beam radiotherapy).
  • Adjuvant therapy was not administered in 34 patients (42%).
  • Metastasis occurred in 10 patients (13%) at a median of 9 months (range, 6-57 months) following enucleation.
  • Eight (80%) of those who developed metastasis had not received adjuvant therapy.
  • A significant difference (P =.02) was found in the incidence of metastasis between the group that had received adjuvant therapy (4%; 2/46) and the group that had not (24%; 8/34).
  • The beneficial effect of adjuvant therapy was statistically significant in subgroups of patients with massive choroidal infiltration (P =.04) or retrolaminar optic nerve invasion (P =.04).
  • There were no adjuvant therapy-related serious systemic complications.
  • CONCLUSION: Postenucleation adjuvant therapy is safe and effective in significantly reducing the occurrence of metastasis in patients with retinoblastoma manifesting histopathologic high-risk characteristics.
  • [MeSH-major] Eye Enucleation. Retinal Neoplasms / drug therapy. Retinal Neoplasms / radiotherapy. Retinoblastoma / drug therapy. Retinoblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Neoplasm Seeding. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Retinoblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12096963.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Gündüz K, Müftüoglu O, Günalp I, Unal E, Taçyildiz N: Metastatic retinoblastoma clinical features, treatment, and prognosis. Ophthalmology; 2006 Sep;113(9):1558-66
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic retinoblastoma clinical features, treatment, and prognosis.
  • PURPOSE: To evaluate the clinical features, treatment, and prognosis in patients with metastatic retinoblastoma.
  • PARTICIPANTS: Eighteen consecutive patients with metastatic retinoblastoma who were diagnosed and managed at the Oncology Service of Ankara University, Turkey, between January 1999 and January 2005.
  • METHODS: All patients underwent magnetic resonance imaging (MRI) of the orbit and brain, lumbar puncture, bone marrow aspiration, and bone scintigraphy for metastatic evaluation.
  • The status of extraocular spread (optic nerve, extrascleral extension, or both) was assessed based on histopathologic or MRI results.
  • Systemic treatment for metastatic retinoblastoma consisted of chemotherapy and radiotherapy (craniospinal, orbital, or both), if necessary.
  • MAIN OUTCOME MEASURES: Status of extraocular spread, site of metastasis, and survival from metastatic retinoblastoma.
  • All patients with metastatic retinoblastoma had histopathologic or MRI evidence of unilateral extraocular disease characterized by optic nerve involvement, extrascleral extension, or both.
  • Nine of 18 patients experienced central nervous system (CNS) involvement, 5 patients had distant and CNS metastasis, and 4 patients had distant metastasis only.
  • At a mean follow-up of 24 months (range, 4-62), all patients with CNS and concurrent distant and CNS metastasis were deceased.
  • Four patients who had distant metastasis only were alive at a follow-up ranging from 9 to 62 months.
  • CONCLUSIONS: The prognosis for metastatic retinoblastoma is dismal and the presence of CNS involvement may portend an even worse outcome.
  • [MeSH-major] Retinal Neoplasms / pathology. Retinal Neoplasms / therapy. Retinoblastoma / secondary. Retinoblastoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Child. Child, Preschool. Eye Enucleation. Eye Evisceration. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Optic Nerve Neoplasms / mortality. Optic Nerve Neoplasms / secondary. Optic Nerve Neoplasms / therapy. Orbital Neoplasms / mortality. Orbital Neoplasms / secondary. Orbital Neoplasms / therapy. Prognosis. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828510.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Chantada GL, Fandiño AC, Guitter MR, Raslawski EC, Dominguez JL, Manzitti J, de Dávila MT, Zubizarreta P, Scopinaro M: Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer; 2010 Jul 15;55(1):60-6
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a prospective study for the treatment of unilateral retinoblastoma.
  • The later included postlaminar optic nerve involvement (PLONI) (n = 23), tumor at resection margin of optic nerve (n = 5) or isolated scleral invasion (n = 2).
  • Group 3 received adjuvant chemotherapy including a total eight cycles of carboplatin and etoposide, alternating with cyclophosphamide, idarubicin, and vincristine.
  • Orbital radiotherapy (45 Gy) was given to patients with invasion to the resection margin.
  • Group 4 included patients with metastatic disease (n = 2).
  • They were given neoadjuvant therapy followed by surgery and high-dose chemotherapy and autologous stem cell rescue.
  • Group 3: CNS relapse (n = 1) in a patient with tumor at the resection margin of optic nerve.
  • CONCLUSIONS: The survival of patients with unilateral retinoblastoma was excellent and 60% were spared from adjuvant treatment.
  • Our intensive regimen was likely to be effective for prevention of metastasis in patients with higher risk PRFs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Retinal Neoplasms / therapy. Retinoblastoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Infant. Male. Neoplasm Staging. Prospective Studies. Recurrence. Reproducibility of Results. Risk Factors. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486172.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Stannard C, Sealy R, Hering E, Hough J, Knowles R, Lecuona K, Reddi VB: Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy. Int J Radiat Oncol Biol Phys; 2002 Dec 1;54(5):1446-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy.
  • PURPOSE: Children with retinoblastoma that extends into or through the choroid, sclera, or optic nerve are at risk of developing orbital disease, as well as metastases.
  • Previously, these enucleated orbits were treated with external beam radiotherapy in addition to chemotherapy.
  • In 1983, he developed a technique to irradiate the contents of the orbit while limiting the dose to the bony orbit and eyelids.
  • Thirty-six were treated prophylactically and 21, with tumor at the resection line of the nerve, extrascleral tumor, or metastases, were treated therapeutically.
  • They received a median dose of 34 Gy in 70 h; 30 also received chemotherapy.
  • Children with tumor at the resection line of the nerve also received treatment to the craniospinal axis.
  • Eight of the 13 patients with microscopic extraocular tumor survived a median of 29 months (range 5-156).
  • None of the 8 patients presenting with orbital tumor or metastases survived.
  • No orbital recurrences developed in any of the patients.
  • CONCLUSION: Orbital brachytherapy is an effective method of irradiating the orbit to prevent recurrent tumor, the treatment time is short, and the cosmesis is much more acceptable than with other forms of irradiation.
  • [MeSH-major] Brachytherapy / instrumentation. Brachytherapy / methods. Eye Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Retinoblastoma / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dose-Response Relationship, Radiation. Follow-Up Studies. Hot Temperature. Humans. Infant. Neoplasm Metastasis. Radiometry. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459368.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


26. Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT: Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology; 2000 Dec;107(12):2250-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: The two main outcome measures were ultimate patient management and the development of retinoblastoma metastasis.
  • RESULTS: Of more than 900 consecutive patients with retinoblastoma managed on the Ocular Oncology Service at Wills Eye Hospital in Philadelphia, 11 (1%) had prior vitrectomy in an eye with viable tumor before referral to us for suspected retinoblastoma.
  • Anterior chamber tumor cells were clinically visible in four eyes (36%), hyphema in two eyes (18%), and iris neovascularization in two eyes (18%).
  • Adjuvant treatment was delivered in 10 patients (91%), using orbital radiotherapy in nine patients (82%) and chemotherapy in nine patients (82%).
  • Histopathologic evidence of retinoblastoma invasion was documented in the episclera (two eyes; 18%), anterior chamber (seven eyes; 64%), iris (five eyes; 45%), ciliary body (five eyes; 45%), choroid (three eyes; 27%), and optic nerve (four eyes; 36%; prelaminar, two eyes; postlaminar, two eyes).
  • The vitrectomy ports, Tenon's fascia, cut end of the optic nerve, and orbit were free of tumor.
  • Of the 10 patients who received prophylactic chemotherapy, radiotherapy, or both in addition to enucleation for prevention of retinoblastoma metastasis, none (0%) experienced metastasis or orbital recurrence during the mean follow-up of 7 years (range, 0.2-24 years) from the time of retinoblastoma diagnosis.
  • However, one patient was referred to us after the development of metastatic retinoblastoma, and despite aggressive chemotherapy and radiotherapy after enucleation, died 24 months later.
  • If vitrectomy is performed in an eye with unsuspected retinoblastoma, enucleation combined with adjuvant chemotherapy, radiotherapy, or both without delay is advised to prevent systemic tumor dissemination.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Endophthalmitis / surgery. Eye Enucleation. Eye Infections, Parasitic / surgery. Female. Humans. Male. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Vitreous Hemorrhage / surgery

  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11097606.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Mori H, Maekawa N, Satoda N, Otsuka N, Sakai N, Fukuse T: [A case of primary lung cancer with initial symptoms due to orbital metastases]. Nihon Kokyuki Gakkai Zasshi; 2003 Jan;41(1):19-24
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We encountered a case of lung cancer in which symptoms due to orbital metastasis were recognized.
  • Orbital MR image demonstrated a right intraorbital mass with bone destruction, which resulted in oculomotor nerve palsy and optic nerve disturbance.
  • Based on the clinical findings, we believed that the orbital tumor was a metastasis from the lung.
  • Systemic chemotherapy and irradiation of the right orbital tumor and the left knee joint were performed.
  • Though a favorable response was achieved in ocular movement, the patient died 3 months after initial treatment because of progression of the primary lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Orbital Neoplasms / secondary
  • [MeSH-minor] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12693000.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


28. Shields JA, Perez N, Shields CL, Singh AD, Eagle RC Jr: Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection. Ophthalmic Surg Lasers; 2002 Sep-Oct;33(5):416-20
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for orbital melanoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital melanoma metastatic from contralateral choroid: management by complete surgical resection.
  • We discuss a clinicopathologic correlation of orbital metastasis from a contralateral choroidal melanoma wherein the orbital tumor was removed completely by surgical resection.
  • The tumor responded well but recurred after 9 years, necessitating enucleation.
  • In August 1999, 17 years after initial presentation, metastatic melanoma to liver, lung, and brain were found and the patient had a favorable response to chemotherapy and brain irradiation.
  • Five months later, in November 2000, an enlarging orbital mass was documented to be compressing the left optic nerve.
  • Complete surgical removal of the tumor was achieved by a superotemporal orbitotomy.
  • Histopathologically, the tumor was a malignant melanoma with features similar to the choroidal tumor.
  • The contralateral orbit can be the site of late metastasis from choroidal melanoma.
  • In rare instances, an orbital metastasis can be completely removed surgically without subjecting the patient to orbital irradiation.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary. Orbital Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12358296.001).
  • [ISSN] 1082-3069
  • [Journal-full-title] Ophthalmic surgery and lasers
  • [ISO-abbreviation] Ophthalmic Surg Lasers
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


29. Cuenca A, Giron F, Castro D, Fandiño A, Guitter M, de Dávila MT, Chantada G: Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol; 2009 Aug;127(8):1006-10
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed all pathology slides of patients with microscopic scleral invasion who were included in 3 prospective treatment protocols (1988-2007).
  • All patients received adjuvant chemotherapy (moderately intensive chemotherapy in the first 2 protocols or a more intensive combination in the third one).
  • Of these cases, 20 had tumor invading the optic nerve beyond the lamina cribrosa, with 6 of these having tumor at the surgical margin.
  • Sixteen were treated with moderately intensive chemotherapy and 16 received a higher-intensity regimen.
  • Seven patients had an extraocular relapse (central nervous system metastasis, n = 4; systemic metastasis, n = 2; and involving the orbit, n = 3, isolated in 1 and combined with central nervous system disease in 2).
  • CONCLUSIONS: Microscopic scleral invasion might be a risk factor for extraocular relapse, and more intensive chemotherapy results in improved survival for these patients.
  • [MeSH-major] Eye Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Retinal Neoplasms / pathology. Retinoblastoma / pathology. Scleral Diseases / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Invasiveness. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667337.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Gupta R, Vemuganti GK, Reddy VA, Honavar SG: Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med; 2009 Aug;133(8):1210-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The presence of histopathologic risk factors is associated with development of metastasis in a patient with retinoblastoma.
  • Adjuvant chemotherapy administered to such patients decreases the risk of metastasis.
  • RESULTS: Histopathologic risk factors were present in 54.2% of 142 eyes enucleated for retinoblastoma and included infiltration of iris (7%), ciliary body (9%), choroid (40%), optic nerve lamina cribrosa (11%), retrolaminar optic nerve (17%), optic nerve to the line of transection (8%), sclera (9%), and extrascleral structures (6%).
  • On multivariate logistic regression analysis, age greater than 24 months and iris neovascularization correlated with infiltration of the choroid, while iris neovascularization correlated with infiltration of the retrolaminar optic nerve.
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Eye / pathology. Eye Enucleation. Female. Humans. India / epidemiology. Infant. Logistic Models. Male. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653711.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, Pfister DG, Zelefsky MJ, Shah JP, Kraus DH, Lee NY: Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):763-9
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate long-term outcomes and toxicity in patients with unresectable paranasal sinus carcinoma treated with radiotherapy, with or without chemotherapy.
  • METHODS AND MATERIALS: Between January 1990 and December 2006, 39 patients with unresectable Stage IVB paranasal sinus carcinoma were treated definitively with chemotherapy plus radiotherapy (n = 35, 90%) or with radiotherapy alone (n = 4, 10%).
  • Patients were treated with three-dimensional conformal radiotherapy (n = 18, 46%), intensity-modulated radiotherapy (n = 12, 31%), or conventional radiotherapy (n = 9, 23%) to a median treatment dose of 70 Gy.
  • Most patients received concurrent platinum-based chemotherapy (n = 32, 82%) and/or concomitant boost radiotherapy (n = 29, 74%).
  • RESULTS: With a median follow-up of 90 months, the 5-year local progression-free survival, regional progression-free survival, distant metastasis-free survival, disease-free survival, and overall survival were 21%, 61%, 51%, 14%, and 15%, respectively.
  • Nine patients developed neck relapses; however none of the 4 patients receiving elective neck irradiation had a nodal relapse.
  • In 13 patients acute Grade 3 mucositis developed.
  • Severe late toxicities occurred in 2 patients with radionecrosis and 1 patient with unilateral blindness 7 years after intensity-modulated radiation therapy (77 Gy to the optic nerve).
  • The only significant factor for improved local progression-free survival and overall survival was a biologically equivalent dose of radiation >/=65 Gy.
  • CONCLUSIONS: Treatment outcomes for unresectable paranasal sinus carcinoma are poor, and combined-modality treatment is needed that is both more effective and associated with less morbidity.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Patient Selection. Platinum Compounds / therapeutic use. Radiotherapy Dosage. Radiotherapy, Conformal / methods. Radiotherapy, Intensity-Modulated / methods. Survival Analysis. Survivors. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395361.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platinum Compounds
  •  go-up   go-down


32. Padovani L, Pommier P, Clippe S S, Martel-Lafay I, Malet C, Poupart M, Zrounba P, Ceruse P, Desmes S, Carrie C, Montbarbon X, Ginestet C: Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):169-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven patients received chemotherapy (concomitant with RT in four).
  • The following quality indexes were defined for the 95% and 90% isodoses: tumor conformity index, normal tissue conformity index, and global conformity index.
  • RESULTS: The median radiation dose to the planned treatment volume was 63 Gy, with a minimal dose of 60 Gy, except in 2 patients whose cancer progressed during RT.
  • The maximal doses tolerated by the structures involved in vision were respected, except for tumors that involved the optic nerve.
  • After a median follow-up of 25 months, 14 local tumor recurrences developed.
  • The radiation dose and tumor conformity index value were not significant prognostic indicators.
  • Two patients died of acute infectious toxicity, and two developed late ipsilateral ocular toxicity.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Ethmoid Sinus. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Follow-Up Studies. Humans. Life Tables. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694835.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Soldevilla HF, Molina RM, Navarra SV: Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness. Int J Rheum Dis; 2010 May;13(2):164-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She underwent modified radical mastectomy of the right breast, and pathologic report revealed diffuse, small cell, non-Hodgkin's lymphoma of the breast; axillary lymph nodes were negative for tumor.
  • She opted for alternative therapy and did not return to the clinic until 7 months later when she developed sudden monocular blindness in the right eye with no other systemic manifestations.
  • Magnetic resonance imaging (MRI) revealed swelling and enhancement of intracanalicular and pre-chiasmatic segments of the right optic nerve and right side of the optic chiasm.
  • She received pulse methylprednisolone therapy (1 g/day for 3 days) with partial recovery of vision.
  • She is scheduled for lymphoma chemotherapy to include rituximab.
  • [MeSH-minor] Aged. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Mastectomy, Radical. Methylprednisolone / therapeutic use. Neoplasm Metastasis / diagnosis. Neuromyelitis Optica / diagnosis. Prednisone / therapeutic use. Radiography, Thoracic

  • Genetic Alliance. consumer health - Blindness.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20536602.001).
  • [ISSN] 1756-185X
  • [Journal-full-title] International journal of rheumatic diseases
  • [ISO-abbreviation] Int J Rheum Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


34. Weber DC, Rutz HP, Bolsi A, Pedroni E, Coray A, Jermann M, Lomax AJ, Hug EB, Goitein G: Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):865-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spot scanning proton therapy in the curative treatment of adult patients with sarcoma: the Paul Scherrer institute experience.
  • PURPOSE: To assess the safety and efficacy of spot scanning proton beam therapy (PT) in the curative treatment of soft-tissue sarcoma (STS) in adults patients.
  • Tumor histology varied with the most common histologic subtypes including liposarcoma and peripheral nerve sheet tumor.
  • All tumors were located in vicinity of critical structures, such as the spinal cord, optic apparatus, bowel, kidney, or bowel.
  • Of the patients, 6 and 5 patients received PT either as adjuvant therapy for non-R0 resection or for recurrence, respectively.
  • The median prescribed dose was 69.4 CGE (CGE = proton Gy x 1.1)-Gy (range, 50.4-76.0) at 1.8 to 2 CGE-Gy (median, 1.9) per fraction.
  • Pre-PT anthracycline-based chemotherapy was delivered to 3 patients only.
  • Local recurrence developed in 3 (23%) patients.
  • The administered dose to these patients was < or =60 Gy-CGE.
  • Distant control was achieved in all but 2 patients (lung metastasis), 1 of whom presented with a concomitant local recurrence.
  • The 4-year local control and metastasis-free survival rates were 74.1% and 84.6%, respectively.
  • CONCLUSIONS: Spot scanning PT is an effective and safe treatment for patient with STS in critical locations.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Protons / therapeutic use. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant / adverse effects. Switzerland. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17606333.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down






Advertisement